TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
KTRADelisted Stock | USD 6.30 0.14 2.17% |
About 62% of Kintara Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Kintara Therapeutics suggests that many traders are alarmed regarding Kintara Therapeutics' prospects. The current market sentiment, together with Kintara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Kintara Therapeutics stock news signals to limit their universe of possible portfolio assets.
Kintara |
TuHURA Biosciences, Inc. , a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy and Kintara Therapeutics, Inc. , a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive results from the primary analysis of TuHURAs completed Phase 1b trial evaluating IFx-2.0 among patients with advanced or metastatic MCC or cSCC who exhibite
Read at finance.yahoo.com
Kintara Therapeutics Fundamental Analysis
We analyze Kintara Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Kintara Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Kintara Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kintara Therapeutics stock to make a market-neutral strategy. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics with similar companies.
Peers
Kintara Therapeutics Related Equities
ONCY | Oncolytics Biotech | 1.85 | ||||
MCRB | Seres Therapeutics | 1.59 | ||||
SCPH | Scpharmaceuticals | 0.31 | ||||
LUMO | Lumos Pharma | 0.23 | ||||
SLRX | Salarius Pharmaceuticals | 0.00 | ||||
MIST | Milestone Pharmaceuticals | 0.00 | ||||
LSTA | Lisata Therapeutics | 0.00 | ||||
TOVX | Theriva Biologics | 0.85 | ||||
CLRB | Cellectar Biosciences | 0.88 | ||||
VCNX | Vaccinex | 1.08 | ||||
DMAC | DiaMedica Therapeutics | 1.30 | ||||
GOVX | GeoVax Labs | 2.55 | ||||
BOLT | Bolt Biotherapeutics | 2.83 | ||||
SABS | SAB Biotherapeutics | 2.94 | ||||
DYAI | Dyadic International | 8.59 | ||||
FBRX | Forte Biosciences | 18.10 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Transaction History View history of all your transactions and understand their impact on performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |